HAROLD SHINE to Genetic Therapy
This is a "connection" page, showing publications HAROLD SHINE has written about Genetic Therapy.
Connection Strength
0.285
-
Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome. Brain Res. 1995 Sep 11; 691(1-2):76-82.
Score: 0.092
-
Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994 Nov 01; 39(4):506-11.
Score: 0.087
-
Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury. J Neurosci Res. 2003 Oct 15; 74(2):221-6.
Score: 0.040
-
Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther. 2000 Feb; 1(2):195-203.
Score: 0.031
-
Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 1994 Apr 12; 91(8):3054-7.
Score: 0.021
-
Glial cell-derived neurotrophic factor gene delivery enhances survival of human corneal epithelium in culture and the overexpression of GDNF in bioengineered constructs. Exp Eye Res. 2008 Dec; 87(6):580-6.
Score: 0.014